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MaMitral regurgitation (MR) is the most common valve disease in the United States. However, a signiﬁcant number of
patients are denied surgery due to increased age, poor ventricular function, or associated comorbidities, putting them
at high risk for adverse events. Moreover, the beneﬁt of surgery for MR is unclear in patients with functional (secondary)
MR. Recently, percutaneous repair of the mitral valve with a particular device (MitraClip, Abbott, Menlo Park, California)
has emerged as a novel therapeutic option for patients with secondary MR or those deemed to be high risk for surgery.
We review data from its initial concept through clinical trials and current data available from several registries. We
focused on lessons learned regarding adequate patient selection, along with current and future perspectives on the use
of device therapy for the treatment of MR. (J Am Coll Cardiol 2014;64:2688–700) © 2014 by the American College of
Cardiology Foundation.M itral regurgitation (MR) is the most com-mon valve disease in the United States(1,2). Worldwide, there are an estimated
50,000 operations for MR per year, of which about
55% are isolated mitral valve (MV) procedures (3).
Patients with severe MR need to be monitored to
prevent the consequences of chronic volume over-
load, such as: shortness of breath, heart failure, pul-
monary hypertension, and reduced left ventricular
(LV) function. Additionally, chronic severe MR leads
to enlargement of the left atrium (LA).
MR pathogenesis can be divided into either a pri-
mary abnormality of the valve, degenerative mitral
regurgitation (DMR) (Figures 1A to 1C), or an abnor-
mality secondary to LV dysfunction, functional mitral
regurgitation (FMR). Mixed situations, involving both
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AB BR E V I A T I O N S
AND ACRONYM S
DMR = degenerative mitral
regurgitation
EF = ejection fraction
FC = functional class
FMR = functional mitral
regurgitation
HRR = high-risk registry
LA = left atrium
LV = left ventricular
MR = mitral regurgitation
MV = mitral valve
NYHA = New York Heart
Association
STS = Society of Thoracic
Surgeons
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2689symptomatic patients with secondary (functional)
severe MR (6). In these cases, there is no consistent
data showing improved outcomes with surgery in
terms of patient survival or quality of life (7,8). A
recent analysis from Europe showed that about one-
half of patients with severe symptomatic MR are
denied surgery, mostly due to older age, impaired ven-
tricular function, and associated comorbidities (9).
In the early 1990s, Alﬁeri developed the surgical
edge-to-edge technique to treat MR (10,11). The
edge-to-edge technique consists of suturing the free
leaﬂet edges in the midportion of the anterior and
posterior MV leaﬂets, creating a double oriﬁce valve.
Whether treating FMR or DMR, surgical edge-to-edge
repair of the MV is generally associated with implan-
tation of a ﬂexible or semirigid prosthetic ring
to increase the coaptation surface. Alﬁeri’s group
found this technique to be safe and durable. It is less
optimal in patients with complex MR or with ischemic
or functional etiology. Edge-to-edge repair with a
ﬂexible band had good short-term results in ischemic
MR, but there was a high recurrence of $3þ MR
in this patient group (12). Edge-to-edge repair’s effec-
tiveness has been debated because of variable results,
a perceived nonphysiological approach, and the po-
tential risk of causing secondary mitral stenosis.
The MitraClip System (Abbott, Menlo Park,
California) was developed on the basis of Alﬁeri’s
edge-to-edge technique (Figure 2). The ﬁrst porcine
experience demonstrating feasibility was reported
in 2003 (13), and the ﬁrst human case was performed
the same year (14). The percutaneously-delivered
device (Figure 3) reduces MR by approximating the
anterior and posterior MV leaﬂets. The procedure is
done under ﬂuoroscopic and echocardiographic
guidance (15). Figure 4 demonstrates the steps in de-
vice deployment. The system is introduced through
the femoral vein and is advanced under ﬂuoroscopic
and echocardiographic guidance into the LA through
a transseptal puncture. After being oriented per-
pendicular to the line of coaptation of the anterior
and posterior MV leaﬂets in the LA, the system is
advanced into the LV, where the anterior and poste-
rior MV leaﬂets are grasped, creating a double MV
oriﬁce. If necessary, more than 1 clip can be deployed
to achieve adequate MR reduction.
PATIENT ELIGIBILITY CRITERIA
Table 1 deﬁnes and Figure 5 demonstrates the echo-
cardiographic criteria for inclusion and exclusion of
patients for the procedure on the basis of criteria used
in U.S. clinical trials (16) and from additional experi-
ence in other locations (17). At present, this procedureis mostly used for central MR. However, in-
vestigators have started using the device for
noncentral MR, where the medial or lateral
scallops are involved, and in patients with
moderate to severe MR after failed MV
annuloplasty rings.
EVOLVING EXPERIENCE
INITIAL EXPERIENCE AND COMPARISON TO
SURGERY. Major studies and their outcomes are
summarized inTable 2 and theCentral Illustration.
The ﬁrst trial to evaluate MitraClip safety, EVER-
EST I (Endovascular Valve Edge-to-Edge REpair
Study) (18),demonstrated its safetyandfeasibility
for treatment of MR. Hemodynamic improve-
ment of patients was noted post-procedure;
however, 30% of patients had surgery due to MR
$3þ within 3 years of the procedure (19). Subsequently,
EVEREST II, a multicenter, randomized controlled trial,
compared percutaneous repair versus surgery (either
replacement or repair) (15) in patients with symptomatic
severeMR($3þ)whowerealsocandidates forMVsurgery.
Of note, as this study randomized surgery-eligible
patients, those with severe LV dysfunction (ejection
fraction [EF] #25%) or LV end-systolic dimensions
>55 mm were excluded. The 279 patients were ran-
domized in a 2:1 ratio in favor of percutaneous ther-
apy. FMR was present in 27% of patients, and 52% of
patients were New York Heart Association (NYHA)
functional class (FC) III or IV (16). In the intention-
to-treat analysis, both groups exhibited similar MR
reductions at 1 year (MR reduction to #2þ was 80%
for surgery and 79% for percutaneous repair, p ¼ 1).
However, patients assigned to a speciﬁc arm but who
did not undergo the procedure (15 of 95 patients
referred for surgery, 6 for percutaneous repair) were
considered to have the same degree of MR at follow-
up, accounting for most patients in the surgery
group with residual MR. Among those assigned to and
treated with surgery, only 4% had grade 3þ or 4þ
mitral regurgitation at 1 year of follow-up, compared
with 19% of those assigned to and treated with the
device. In retrospect, the suboptimal reduction of
MR using percutaneous therapy in this study may
have been due to a number of factors: lack of operator
experience (only 4 of 37 centers had performed more
than 20 cases); suboptimal patient selection; and, in
many cases, insufﬁcient use of a second clip. It should
be noted that this procedure has a signiﬁcant learning
curve. Schillinger et al. (20) found that procedural
times progressively decrease after 25, 50, and 75
percutaneous valve repair cases. Similar ﬁndings
support the importance of the learning curve for
FIGURE 1 Pathogenesis of MR
(Top) primary, degenerative mitral regurgitation (MR), and (bottom) secondary, functional MR. (A) 2-dimensional transesophageal echocar-
diogram (TEE) demonstrating prolapse of the posterior middle segment of the mitral valve (MV) (arrow). (B) Color-ﬂow Doppler shows an
extensive, eccentric, anteriorly-directed regurgitation jet, signifying the presence of severe MR. (C) In this 3-dimensional TEE en face view,
the middle part of the posterior mitral valve leaﬂet is clearly seen prolapsed, corresponding to the 2-dimensional ﬁndings (arrow). (D)
TEE demonstrating normal MV leaﬂet morphology; however, there is tenting of both MV leaﬂets, predominantly of the posterior leaﬂet
(arrowhead). (E) Color-ﬂow Doppler shows an extensive, eccentric, posteriorly-directed regurgitation jet, signifying the presence of severe MR.
(F) In this 3-dimensional TEE en face view, the valve leaﬂet failed to coapt adequately, corresponding to the 2-dimensional ﬁndings (*).
This provides the mechanism for the secondary MR. Ao ¼ aorta, LA ¼ left atrium, LV ¼ left ventricle.
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2690procedure time (18,21). Nevertheless, both surgical
and percutaneous repair patients experienced sig-
niﬁcant improvement in LV dimensions and in
end-systolic and -diastolic volumes at 1 year. Pa-
tients’ quality of life improved from baseline to 1 year
in both study groups, with NYHA FC $III reduced
from 52% to 2% of patients in the percutaneous repair
group and from 47% to 13% in the surgery group at
1 year (p ¼ 0.002). The rate of major adverse events
at 30 days (including death, myocardial infarction,
reoperation due to a failed surgical repair or re-
placement, urgent or emergency cardiovascular sur-
gery for adverse event, major stroke, renal failure,
deep wound infection, mechanical ventilation for
>48 h, gastrointestinal complications requiring sur-
gery, new onset AF, septicemia, and transfusion of $2U of blood) was 15% in the percutaneous repair group
compared with 48% in the surgical group. However,
this was driven mainly by the need for transfusion;
with its exclusion from major outcomes, the rate of
major adverse events at 30 days did not signiﬁcantly
differ between the groups (5% for the percutaneous
repair group vs. 10% in the surgical group). At 4 years
of follow-up of EVEREST II patients, there was no
signiﬁcant difference in mortality between the 2
groups (17% vs. 18%, p ¼ 0.9). MR $3þ was present in
22% of the percutaneous repair group versus 25% of
the surgical group (p ¼ 0.745); however, surgery for
signiﬁcant MV regurgitation occurred in 25% of
percutaneous repair-treated patients versus only
5.5% of surgically-treated patients (p < 0.001), with
most surgeries performed within the ﬁrst year in
FIGURE 3 The System and Dimensions
The MitraClip is shown along with the clip “grippers.” The system dimensions corre-
sponding to requirements for inclusion of patients for the procedure are indicated. (A) Arm
width; (B) closed clip length; (C) arm length (coaptation length); (D) grasping width with
the grippers open to 120; and (E) clip width with the grippers open to 180. Images
provided courtesy of Abbott Vascular ª 2014. All rights reserved.
FIGURE 2 A Double-Oriﬁce Valve Post-Procedure
Views of the mitral valve from (A) above (left atrium) and (B) below (left ventricle)
showing the characteristic double oriﬁce after device deployment, similar to results ob-
tained from the surgical Alﬁeri stich. A ¼ anterior mitral valve leaﬂet; Ao ¼ aorta;
P ¼ posterior mitral valve leaﬂet. Asterisk marks the tissue bridge between the anterior
and posterior mitral leaﬂet created by the MitraClip.
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NYHA FC at 1 year was sustained at 4 years, with
94% of the total study cohort with NYHA FC #II (22).
The 5-year results were recently presented and
demonstrated no mortality difference between the
2 groups, a low rate of MV surgery in the percuta-
neous repair group beyond the ﬁrst 6 months of
therapy, and a low rate of adverse events from 1 to
5 years in both groups (23).
SELECTED PATIENT POPULATIONS
HIGH-RISK PATIENTS. The percutaneous repair pro-
cedure appears to be a good option for patients who
are too frail to undergo surgery (9). The EVEREST II
High Risk Registry (HRR) (24), a prospective, single-
arm study, was conducted in North America to
gather clinical data on the effectiveness and safety
of percutaneous valve repair in 78 patients deemed
to be at high risk for surgery (Society of Thoracic
Surgeons [STS]) mortality risk $12%) with MR $3þ.
As in EVEREST II, patients were excluded due to
severe LV dysfunction (those with EF #25% or LV
end-systolic dimensions >55 mm). Procedural results
were relatively comparable to the original EVEREST II
trial, with 74% of patients with NYHA FC #II and 78%
free from MR $3þ at 1 year. There were no procedural
deaths or device embolizations (Central Illustration,
Table 3). The REALISM (Real World Expanded Multi-
center Study of the MitraClip System) continued-
access registry, which enrolled both standard and
high-risk patients, was designed to collect “real-
world” data and provide additional effectiveness and
safety data. Eligibility criteria are similar to those for
the EVEREST II HRR. The REALISM cohort’s high-risk
group, which enrolled its last patient in November
2013, includes patients on average 10 years older than
those randomized in the EVEREST II trial and with
more severe comorbidities (STS score of 11.3 vs. 4.6),
predominantly with FMR (70% vs. 27%), and with a
lower EF (47  14% vs. 60  10%). Initial analysis from
this cohort showed that MR reduction from 3þ or 4þ
(moderate to severe or severe MR) to 2þ (moderate
MR) is associated with a decrease in LA and LV size
(reverse remodeling). Although there was a reduction
in LA size and reduction of the LV end-diastolic vol-
ume in patients with DMR (suggesting correction of
the primary volume overload), in patients with FMR,
there was a reduction in LA size and both LV end-
systolic and -diastolic volumes, suggesting reverse
LV remodeling. The magnitude of reverse remodeling
was similar whether MR was reduced to either 2þ or
1þ. The sustained reduction in MR also translated
into clinical beneﬁts, such as improvement infunctional class and reduction in hospitalization due
to heart failure (25).
In 2008, the MitraClip system received approval for
use in Europe. On the basis of wide experience and
clinical evidence from trials and registries, the latest
European Society of Cardiology guidelines on the
management of patients with valvular heart disease
FIGURE 4 Steps of Deployment
These 2- and 3-dimensional TEE images show the steps of MitraClip deployment. (A) Trans-septal puncture. (B) Introduction of the catheter
system to the LA through the intra-atrial septum (IAS). (C) Advancement of the delivery system and positioning of the MitraClip in between the
MV leaﬂets. (D) 2-dimensional TEE demonstrating positioning of the MitraClip between the anterior and posterior MV leaﬂets. (E) 2-
dimensional TEE with color Doppler showing mild MR after deployment of the percutaneous valve repair system. (F) 3-dimensional TEE
showing the result post-deployment along with the typical double-oriﬁce appearance. Fluoroscopic images showing the device within the LA
(G), advanced towards the LV (H), and post-deployment (I). Asterisk points to the location of the MitraClip. Abbreviations as in Figures 1 and 2.
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ment option for patients with symptomatic severe MR
who were inoperable or at high surgical risk with a life
expectancy of >1 year (Class IIb, Level of Evidence: C)
(26). Since its approval in Europe, more than 16,000
percutaneous repair procedures have been performed
worldwide. The ACCESS-EU (Two-Phase Observa-
tional Study of the MitraClip System in Europe)
observational study (27) consisted of 567 elderly
(mean age 74 years), high-risk (logistic EuroSCORE
of 23  18.3) patients, with predominantly FMR
(69%), low EF (53% with EF #40%), low functionalstatus (85% in NYHA FC $III), and multiple com-
orbidities, who underwent the device therapy at
14 European centers. There was a high procedural
success rate of 99.6%. The procedure was found to be
safe, with a 30-day mortality rate of 3.4% (19 pa-
tients). At 1 year, 82% of the patients were alive.
Procedural adverse events were low and included 36
patients (6.3%) who subsequently underwent MV
surgery within 12 months of device therapy. At 1 year,
signiﬁcant improvement in MR grade was observed,
with 79% of patients having #2þ MR and 71% of pa-
tients at NYHA FC #II. Positive outcomes with
TABLE 1 Echocardiographic Morphological Characteristics for
Determining Patient Eligibility for Percutaneous Valve Repair Therapy
Criteria Suggesting
Patient Suitability
Criteria Suggesting Patient
Might Not Be Suitable
Nonrheumatic etiology Rheumatic etiology, endocarditis-related
valve disease, or prior MV surgery
Central mitral regurgitation jet Cleft or perforated mitral leaﬂets
MV oriﬁce area $40 mm2 Lack of secondary chordal support
If a ﬂail leaﬂet is present Posterior leaﬂet length <7 mm
Flail gap* <10 mm
Flail width* <15 mm
Posterior leaﬂet length $10 mm Leaﬂet gap >2 mm
If leaﬂet tethering present Presence of severe calciﬁcations in the
grasping area
Coaptation depth <11 mm
Coaptation length† <10 mm
Absence of calciﬁcations in the
grasping area
Transmitral pressure gradient $4 mm Hg‡
Effective regurgitant oriﬁce area >70.8 mm2‡
MV oriﬁce area <30 mm2‡
Evidence of intracardiac mass, thrombus,
or vegetation, or evidence of an inferior
vena cava or femoral venous thrombus
Patient eligibility characteristics were on the basis of criteria used in the EVEREST trial (16). See
Figure 5 for corresponding images. *These criteria are derived from the device design (see also
Figure 3). The MitraClip arm width is 5 mm, thus a ﬂail width of more than 15 mm would
necessitate implantation of many clips and adversely cause valve obstruction. The arm length,
when fully open at 180 , is 20 mm. As both clip arms close simultaneously, if the distance be-
tween the leaﬂets is too great, it would be more than difﬁcult to grasp both simultaneously
(Figure 5). †If the gap between the leaﬂets is too big, the clip will not be able to build a sufﬁcient
tissue bridge (Figure 5). ‡On the basis of ﬁndings from Lubos et al. (17): patients with these
ﬁndings carry an increased risk of procedural failure.
MV ¼ mitral valve.
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2693MitraClip were also observed in the German TRAMI
(Transcatheter Mitral Valve Interventions) registry,
which to date includes 1,064 patients who are older
and with more comorbidities than those initially
enrolled in the EVEREST II trial (28,29). Analysis from
the TRAMI registry, speciﬁcally looking at patients
older than age 76 years (29), showed that, similar to
younger patients, elderly patients may beneﬁt from
device therapy, with a procedural success rate of 95%
along with a reduction in MR #2þ in 96% of patients.
During follow-up of about 2.5 months, there was also
comparable improvement in NYHA FC, with 76% of
the entire cohort in NYHA FC #II; however, death
was higher in the elderly patient group (9% vs. 15%,
p < 0.05). Results from a systematic review of 16
studies (12 from Europe and 4 from the United States;
13 prospective and 3 retrospective), including data on
2,980 patients, 2,689 of who were considered to be at
high risk for surgery, showed that during a mean
follow-up of 310 days (range 80 days to 4 years), the
number of patients with $3þ MR was signiﬁcantly
reduced from 96.3% to 14.7% and the number of pa-
tients reporting NYHA FC $III symptoms decreased
from 83% to 23.4% at the end of follow-up (30). A
recent meta-analysis of cohorts, including high-risk
patients, who underwent percutaneous valve repair
therapy, found that procedural success (MR #2þ)
between 73% and 100% was achieved. The 30-day
mortality ranged from 0% to 7.8%. At 6 to 12
months, 61% to 99% of patients reported #2þ MR. At
1 year, patient survival in this meta-analysis was 75%
to 90% (31).
PRIMARY VERSUS SECONDARY MR. For the young
patient with DMR and without comorbidities, surgical
MV repair can be performed with minimal risk and
good results. However, the durability of MV surgical
repair is an issue. There are variable results regarding
freedom from recurrence of moderate or severe MR
($3þ). Flameng et al. (32) found a recurrence rate
of $3þ MR of 35% at 10 years, for which Barlow’s
disease was a risk factor. David et al. (33,34) reported
a recurrence rate of 35% at 12 years when the anterior
mitral leaﬂet was involved. Conversely, more
contemporary studies from multiple centers reported
that surgical repair is durable and survival is
improved, with a low reoperation rate (35–38). A
recently published analysis from the EVEREST cohort
of 127 patients with DMR, mean age 82 years, 87%
NYHA FC $III, and prohibitive surgical risk (regarded
as STS risk $8%, porcelain aorta or extensively
calciﬁed ascending aorta, frailty, severe liver disease,
severe pulmonary hypertension, or other unusual
extenuating circumstances) found percutaneous
repair therapy successful in 95%. Death was 6.3% at30 days and 23.6% at 1 year. At 1 year, 83% of patients
had MR grade #2þ and 87% were in NYHA FC #II,
compared with all having MR $3þ and 87% at NYHA
FC $III at baseline. At 12 months, MR reduction
to #2þ was associated with improvement in NYHA
FC, improved quality of life, reduced hospitalization
for heart failure, and reverse LV remodeling. More-
over, patients with MR grade #2þ at discharge
demonstrated better survival at 12 months than those
discharged with MR $3þ (39). A subanalysis of 117
high-risk patients, all with DMR, from the ACCESS-EU
registry showed that percutaneous repair therapy
reduced MR signiﬁcantly, with 75% of patients with
an MR grade of #2þ at 1 year and 81% with NYHA
FC #II (40).
A survival beneﬁt with surgery has not been
demonstrated in patients with secondary FMR (41).
Moderate or severe regurgitation has been reported in
up to 30% of FMR patients at 1 to 5 years post-repair,
prompting some surgeons to consider either MV
replacement or not addressing the problem of FMR
surgically (42,43). In the EVEREST II 4-year outcome
subgroup analysis, DMR patients had greater beneﬁt
from surgery compared with percutaneous valve
repair. However, in FMR patients at high risk for
recurrent MR after surgery (44), the efﬁcacy endpoint
FIGURE 5 Echocardiographic Measurements for Determining Patient Suitability for MitraClip Implantation
(A and B) 3-dimensional TEE en face views demonstrating measurements of a ﬂail width (red brackets) in patients with degenerative mitral valve disease. These
measurements can be obtained alternatively from short-axis views where the ﬂail width is largest (transthoracic echocardiogram/TEE; transgastric not shown). (A) An
example of a suitable case for the percutaneous valve repair system, with a small ﬂail width (ideally <15 mm). The pathology is located centrally. (B) An example of a
case that is not suitable for percutaneous valve repair therapy due to multiple, extensive prolapses in the posterior mitral leaﬂet (PML). (C and D) 2-dimensional TEE
images showing the ﬂail gap. Yellow brackets indicate the distance between the tip of the anterior mitral leaﬂet (AML) and PML. This measurement should be taken in
long-axis views, where the ﬂail gap is largest (TEE 4-chamber, 5-chamber, long-axis vieww120 to 150). (C) An example of a case with a suitable ﬂail gap (<10 mm).
(D) The ﬂail gap is too large, in addition to the posterior leaﬂet being considerably calciﬁed, making this case unsuitable for percutaneous valve repair therapy. (E and F)
Measurements of the mitral valve area (MVA) from the LV side (post-processing analysis using QLAB software, Philips, Eindhoven, the Netherlands) are shown. (E) A case
with a MVA (A1) of 5.78 cm2, which is suitable for device implantation (>4 cm2). (F) The MVA (A1) is 2.17 cm2, a contraindication to percutaneous device implantation.
(G and H) Examples of patients with functional mitral regurgitation. The tenting height (which equals the coaptation depth, demonstrated by the yellow double arrow) is
measured from the base of the mitral annulus (green dashed line) to the tip of the leaﬂets in diastole. This measurement should be taken in either the 4- or 5-chamber
view, where the tenting height is largest. The tenting height should ideally be <11 mm. (G) A suitable case; (H) severe retraction of both leaﬂets is seen, and the case is
unsuitable for percutaneous valve repair therapy. To be a suitable candidate for percutaneous therapy, the coaptation length (overlap of the tip of the AML and the PML
at the edges) should optimally be$2 mm. The measurement should be taken in long-axis views, where the coaptation length is shortest. (G) There is some overlap of the
AML and the PML (red arrows). (H) The tips of the leaﬂets just touch, without demonstrating real overlap; thus, this case is not ideal for device implantation (red arrow).
Abbreviations as in Figure 1.
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2694was 34% in the percutaneous repair group versus
23% in the surgical group (p ¼ 0.344). Of subjects
with $3þ MR at 4 years, FMR was more prevalent in
the surgical arm (22). Worsening LV dysfunction is
also not an uncommon post-operative occurrence in
patients with MR (45,46). In the past, this was
attributed to the increase in afterload associated with
surgical correction of MR. However, studies of the
hemodynamic effects of the device therapy demon-
strated that, in patients with LV dysfunction, the
cardiac output increases, and LV and LA ﬁlling pres-
sures, as well as pulmonary artery systolic pressures,
are reduced (19,47,48). There have been no reportedinstances of low cardiac output syndrome as a
consequence of percutaneous device therapy. Thus,
reducing MR does not appear to promote post-
procedural LV dysfunction. It is likely that the post-
operative LV dysfunction seen in post-surgery
patients might be attributed to several factors,
including the systemic inﬂammatory response,
myocardial oxidative stress, and free radical injury
associated with the use of cardiopulmonary bypass
(49), cardioplegia (50), and complete cardiac arrest;
the development of reversed septal motion post-
operatively; and the restraint of mitral annular
motion (LV function) that may be caused by MV
TABLE 2 Characteristics of Patient Populations in MitraClip Trials/Registries
Study (Ref. #) N Study Objective Age, Yrs FMR DMR LVEF Surgical Risk
NYHA
FC $III
EVEREST I (18) 107 Percutaneous valve repair therapy
initial safety, efﬁcacy, and
feasibility
Median: 71, 62%
age >65 yrs
21 79 62 46
EVEREST II (15)
randomized
controlled trial
279 (MitraClip 184;
surgery 95)
Percutaneous therapy vs. surgery Median 67, 29%
age >75 yrs
27 73 60 50
EVEREST II HRR (24) 78 High-risk registry for patients
with STS risk $12%
Mean 77  9.8,
62% age
>75 yrs
59 41 54.4  13.7 Mean STS score
14.2  8.2
90
REALISM continued-
access registry (25)
545 (273 high-risk,
272 non–high-risk)
High-risk study:
351 patients (273 þ 78
from EVEREST II HRR)
Mean 76  11 70 30 47  14 Mean STS score 11.3 85
ACCESS-EU (27)
observational study
567 Post-approval European
registry  18%
Mean 74  9.6 69 31 53% with
LVEF #40%
Mean logistic
EuroSCORE 23
85
TRAMI registry (28,29)
observational study
1,064 German registry designed
to assess device in
daily practice
Median 75,
interquartile
range: 70–81
71 29 30% with
LVEF #40%
EuroSCORE:
18/25*
STS score:
7/11.5*
87
Vakil et al. (30)
systematic
review of
2,980, of which 2,689
were considered
high risk
Pooled analysis (12 European,
4 United States; 13
prospective and 3
retrospective)
Mean 74  0.6 65 35 46  3.2 Mean logistic
EuroSCORE
23.4  1.5
STS score 12  0.7
83
Values are % unless otherwise indicated. *Patients <76/$76 years, respectively.
ACCESS-EU ¼ Two-Phase Observational Study of the MitraClip System in Europe; DMR ¼ degenerative mitral regurgitation; EVEREST ¼ Endovascular Valve Edge-to-Edge REpair Study; FC ¼ functional
class; FMR ¼ functional mitral regurgitation; HRR¼ high-risk registry; LVEF¼ left ventricular ejection fraction; MR ¼mitral regurgitation; MV ¼mitral valve; NYHA¼ New York Heart Association; REALISM¼
Real World Expanded Multicenter Study of the MitraClip System; STS ¼ Society of Thoracic Surgeons; TRAMI ¼ Transcatheter Mitral Valve Interventions.
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2695annuloplasty rings or prosthetic valves. Data from
trials and registries, such as the EVEREST II HRR (24)
(of which 69% of patients had FMR) and those
detailed in Table 4 (21,51–54), support MitraClip
therapy as a valuable treatment option, especially in
those with severely reduced LV function (EF <30%),
where current therapeutic options are limited. In
nonresponders to cardiac resynchronization therapy,
percutaneous valve repair therapy improved NYHA
FC, increased EF, and reduced LV volumes in about
70% of patients (52); a similar improvement in NYHA
FC after cardiac resynchronization therapy failure
was also found by Pleger et al. (55). As demonstrated
in Table 4, data on the device in patients with FMR
shows a reduction in MR, symptomatic improvement
in NYHA FC III to IV patients, and reverse LV
remodeling; there is no data demonstrating
improvement in survival. As shown in the Central
Illustration, data from the REALISM cohort looking
at outcomes by MR etiology show some different
outcomes with regard to LV remodeling when
comparing patients with FMR to those with DMR.
Although LV end-diastolic volume improved propor-
tionally to the degree of MR reduction at 1 year in
both groups, patients with FMR also exhibited a
proportional decrease in LV end-systolic volume,
which was not statistically evident in the DMR group
(25). Additional analyses from small trials, evaluatingpercutaneous therapy in those with FMR, also suggest
that the procedure is safe and effective in this patient
population (21,51–54).
On the basis of pooled results of the percutaneous
valve repair device in high-risk patients with DMR, in
2013 the U.S. Food and Drug Administration approved
device therapy for patients considered to be at pro-
hibitive risk for surgery who have MR $3þ due to
DMR (39). In addition, the 2014 AHA/ACC guidelines
for management of patients with valvular heart dis-
ease included transcatheter MV repair as an option for
patients with primary MR who are symptomatic
despite optimal heart failure therapy and who are at
prohibitive risk for surgery (Class IIb, Level of Evi-
dence: C) (6). Future patient selection for percuta-
neous valve repair could potentially include other
groups of patients where surgical risks are high, as in
FMR (and a reduced LVEF), or where surgical results
are less optimal and durable, such as patients with
anterior leaﬂet prolapse/ﬂail. The ongoing COAPT
(Clinical Outcomes Assessment of the MitraClip
Percutaneous Therapy for High Surgical Risk Patients)
(56) and RESHAPE-HF (Randomized Study of the
MitraClip Device in Heart Failure Patients with Clin-
ically Signiﬁcant Functional Mitral Regurgitation)
(57) trials are evaluating the role of MitraClip in
patients with FMR who are not candidates for
cardiac surgery.
CENTRAL ILLUSTRATION Outcomes of MitraClip Trials/Registries
EVEREST I
107 patients
74 + NA 9.1% 1%
EVEREST II
279 patients
(MitraClip 184
Surgery 95)
1 year
Intention-to-treat analysis:
Surgery 80% MR ≤2+ 
MitraClip 79% MR ≤2+
(p = 1)
Per-protocol analysis:
Surgery 4% MR ≤2+
MitraClip 83% MR ≤2+
(p = 0.01)
4 years
Surgery 75% MR ≤2+
MitraClip 78% MR ≤2+
(p = 1)
1 year
Surgery 87% FC<III
MitraClip 98% FC<III
(p = 0.002)
LV volumes reduced 
significantly from baseline in 
both groups. Reduction in 
end-diastolic volume was 
greater with surgery
30 Days
Intention-to-treat analysis:
Surgery 48%, 
MitraClip 15% 
(p <0.001)*
Per-protocol analysis:
Surgery 57%, 
MitraClip 9.6%
(p <0.001)†
1 year
Intention to treat analysis:
Surgery 37%, 
MitraClip 32.6%
(p = 0.42)
Per protocol analysis:
Surgery 2.2%
MitraClip 17.6%
(p <0.02)
1 year
Intention-to-treat analysis:
Surgery 5.6%, 
MitraClip 6.3%
(p = 1)
Per-protocol analysis:
Surgery 6.8%
MitraClip 4.5%
(p = 0.7)
4 years
Surgery 18%
MitraClip 17%
(p = 0.9)
EVEREST II HRR
78 patients
30 days
73% MR ≤2+
1 year
78% MR ≤2+
30 days
73% FC <III
1 year
74% FC <III
1 case of tamponade during 
transseptal puncture
30 days
7.7%
1 year
24.4%
REALISM
545 patients
(273 high risk 
+ 272 non-high risk)
Discharge
82% MR ≤2+
1 year
FMR 84% MR ≤2+|
DMR 82% MR ≤2+
NA NA NA
ACCESS-EU
567 patients
1 year
79% MR ≤2+
1 year
71% FC <III
1 year
6.3% surgery due
to MV dysfunction
30 days
3.4%
(42% due to cardiac causes)
1 year
18%
TRAMI
1,064 patients
96% MR ≤2+ post-procedure Median follow-up of 85 days
76% FC <III
Median follow-up of 85 days
MV Surgery 2.6%
Peri-procedural
2.8%
Median follow-up of 85 days 
12%
Vakil et al.
Systematic review
of 2,980 patients
During a mean follow-up
of 310 days
85.3% MR ≤2+
Median follow-up of 85 days
76% FC <III
Median follow-up of 85 days
MV Surgery 2.6%
Peri-procedural
2.8%
Median follow-up of 85 days
12%
TRIAL/REVIEW MR REDUCTION NYHA FC IMPROVEMENT ADVERSE EVENTS PATIENT MORTALITY
Beigel, R. et al. J Am Coll Cardiol. 2014; 64(24):2688–700.
*When excluding red blood cell transfusion, there was no signiﬁcant difference in MACE: surgery 10%, MitraClip 5% (p ¼ 0.23). †When excluding red blood
cell transfusion, there was still a signiﬁcant difference in MACE: surgery 11.4%, MitraClip 0.7% (p ¼ 0.001). ACCESS-EU ¼ Two-Phase Observational Study of
the MitraClip System in Europe; DMR ¼ degenerative mitral regurgitation; EVEREST ¼ Endovascular Valve Edge-to-Edge REpair Study; FC ¼ functional class;
FMR ¼ functional mitral regurgitation; HRR ¼ high-risk registry; LV ¼ left ventricular; MACE ¼ major adverse cardiovascular event(s); MR ¼ mitral regurgitation;
MV ¼ mitral valve; NA ¼ not available; NYHA ¼ New York Heart Association; REALISM ¼ Real World Expanded Multicenter Study of the MitraClip System;
TRAMI ¼ Transcatheter Mitral Valve Interventions.
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2696SAFETY
Potential complications associated with MitraClip
implantation are detailed in Table 5. Initial studies of
the percutaneous procedure in EVEREST I, and laterin EVEREST II, showed it to be safe, with low
morbidity. Real-world results from the ACCESS-EU
registry in a higher-risk, older population than
those evaluated in the EVEREST trials show low
procedural and hospital mortality (<2%), with >90%
TABLE 3 Results From Studies Evaluating Effects of Percutaneous Valve Repair on MR, Hemodynamics, and Remodeling
First Author/Study
(Ref. #) MR Grade CO, l/min PCWP, mm Hg Other
Biner/Siegel et al.
(19,47) (N ¼ 107,
patients from
EVEREST I and
roll-in EVEREST
II cohorts)
MR grade reduced:
3.3  0.7 to 1.7  0.9
CO increased: 5  2 to
5.6  1.9 (p ¼ 0.0033)
CI increased: 2.7  1 to
3  1 (l/min/m2)
No change in PCWP
LVEDP fell from 11.4  9 to
8.8  5.8 (p ¼ 0.016)
SVR reduced: 1,253  259 to 1,058  475
dyne/cm5
Right atrial pressure increased by 1 mm Hg from:
8.1  4.7 to 9.3  5.6 mm Hg
No signiﬁcant change in PASP, except in those
with a baseline elevated PASP in whom it fell
from 49  7 mm Hg to 40  9 mm Hg
(p = 0.004)
EVEREST II HRR (24) 75% achieved MR
reduction to #2þ
40% achieved MR of 1þ
At 1 year: 78% with MR #2þ
Pre: 4.6  2.1
10 min post:
5.6  2.7
(p ¼ 0.001)
V-wave decreased:
26  15 to 21.3  9.6
(p ¼ 0.023)
Blood pressure pre: 109.3  21.1 mm Hg
10 min post: 113.5  19.3 mm Hg (p ¼ 0.09)
REALISM (25) 82% MR #2þ at discharge
FMR:
At baseline: 86% MR $3þ
At 1 year: 84% MR #2þ
DMR:
At baseline: 94% MR $3þ
At 1 year: 82% MR #2þ
Reduction in MR severity, even to 2þ, was
associated with reverse LA and LV
remodeling. Patients with FMR showed
signiﬁcant reductions in both LVEDV and
LVESV (in contrast to those with DMR, who
did not show signiﬁcant reduction in LVESV).
ACCESS-EU (27) 91% achieved MR
reduction to #2þ
51% achieved MR #1þ
CO increased:
3.7  1.5 to 4.4  1.9
V-wave decreased:
23  11 to 19.5  9
All other hemodynamic measurements
remained stable
Gaemperli et al.
(48) (N ¼ 50)
92% achieved MR
reduction to #2þ
CI increased:
3.1  1 to 3.9  1.1
(l/min/m2) (p < 0.05)
PCWP decreased:
29  12 to 24  6
All other hemodynamic measurements
remained stable
CI ¼ cardiac index; CO ¼ cardiac output, LA ¼ left atrium; LV ¼ left ventricle; LVEDP ¼ left ventricular end-diastolic pressure; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection
fraction; LVESV ¼ left ventricular end-systolic volume; PASP ¼ pulmonary artery systolic pressure; PCWP ¼ pulmonary capillary wedge pressure, SVR ¼ systemic vascular resistance; other abbreviations as in
Table 2.
J A C C V O L . 6 4 , N O . 2 4 , 2 0 1 4 Beigel et al.
D E C E M B E R 2 3 , 2 0 1 4 : 2 6 8 8 – 7 0 0 Percutaneous Mitral Valve Repair for Severe Mitral Regurgitation
2697procedural success, along with hemodynamic and
functional improvement (27) (Central Illustration,
Table 3). From a pooled analysis of 16 studies
totaling 2,980 patients, of whom 2,689 were
considered high-risk for surgery, there was a very
low incidence of procedural death (0.1%). Thirty-dayTABLE 4 Results of Percutaneous Valve Repair Therapy in FMR
First Author/Study (Ref. #) N Patient Characteristics
Franzen et al. 2010 (21) 51 FMR 69% (35 of 51)
LVEF 36  17%
NYHA FC $III 98%
Logistic EuroSCORE 15  11%
STS score 16  11
Franzen et al. 2011 (51) 50 All with FMR $3þ and LVEF #25%
NYHA FC $III 100%
Logistic EuroSCORE 34  21%
Auricchio et al. 2011 (52) 51 All patients CRT
nonresponders with FMR $3þ
LVEF 27  8.7%
NYHA FC $III 98%
Logistic EuroSCORE 29.7  19.4%
STS score 13.9  14.6
Van den Branden
et al. 2012 (53)
52 FMR, 90% (47 of 51) all $3þ
NYHA FC $III, 98%
Logistic EuroSCORE 27.1  17%
STS score 10.1  7.6
Taramasso et al. 2013 (54) 109 FMR 100%
Logistic EuroSCORE 22  16.5%
82% NYHA FC $III
Mean EF 27  10%
CRT ¼ cardiac resynchronization therapy; EF ¼ ejection fraction; other abbreviations asmortality was 4.2%. During a mean follow-up of 310
days (range 80 days to 4 years), the incidence of
death was 387 of 2,457 (15.8%) (30). The totality of
these data clearly demonstrates this procedure’s
safety compared with other contemporary trans-
catheter valve therapies (58).MR Reduction/NYHA FC Mortality
67% FC <III post-procedure
NYHA FC improvement $1 FC 90%
96% with #2þ MR at 30 days
No mortality at 30 days
92% with MR #2þ at 30 days
87% with MR #2þ at 6 months
72% FC <III at 6 months
6% at 30 days
19% at 6 months
NYHA FC at discharge, 73% (p < 0.001)
More than 85% with MR #2þ at 1 yr
Signiﬁcant reduction of LVESV and
LVEDV at 6 months
Signiﬁcant increase of LVEF
at 6, 12 months
2.1% periprocedural
4.2% at 30 days
18% at a median follow-up
of 14 months
84% NYHA FC <III at 6 months
79% with MR #2þ at 6 months
LVESV, LVEDV: trend in reduction
3.6% (2 patients) periprocedural
11.5% at 6 months
86% NYHA FC <III at 1 yr
70% MR #2þ at 2.5 yrs
Mean EF increased to 34.7  10%
at 1 yr (p ¼ 0.002)
Signiﬁcant reduction in LVEDV at 1 yr
1.8% at 30 days
25% at 3 yrs
in Tables 2 and 3.
TABLE 5 Complications Associated With
Percutaneous Valve Implantation
Partial clip detachment
Thrombus formation on the catheter
Chordae tendineae entrapment by the MitraClip
Pericardial effusion or tamponade
Persistent atrial septal defect
Cardiac arrhythmias
Air embolism
Beigel et al. J A C C V O L . 6 4 , N O . 2 4 , 2 0 1 4
Percutaneous Mitral Valve Repair for Severe Mitral Regurgitation D E C E M B E R 2 3 , 2 0 1 4 : 2 6 8 8 – 7 0 0
2698FUTURE PERSPECTIVES
Percutaneous valve repair therapy appears to have a
favorable risk-beneﬁt ratio in high-risk patient pop-
ulations with both primary MR and FMR. The Mitra-
Clip is currently approved in the United States for
prohibitive-risk primary MR patients. There is still
no randomized data demonstrating that mechanical
reduction of FMR in addition to medical therapy is
superior to medical therapy only.
The 2014 AHA/ACC guidelines have less stringent
criteria for severe FMR than the prior guidelines,which
were used to deﬁne patients previously enrolled into
percutaneous valve repair therapy clinical trials.
Although the new criteria for severe FMR are con-
troversial (59), they potentially allow more patients
with FMR to be candidates for device therapy (if
approved for this indication). The COAPT and
RESHAPE-HF trials will prospectively evaluate per-
cutaneous valve therapy’s usefulness in patients with
FMR, NYHA FC II to IV, and reduced LV function,
by comparing percutaneous valve repair to nonsur-
gical standard of care.
Additional successfully-performed, but not yet
extensively-studied, percutaneous valve applications
include patients with severe MR due to medial and
lateral jets and patientswith failedMV surgical repairs.
Future improvements in devices for edge-to-edge
repair could include: a smaller, complete deliverysystem and device; a device that is catheter-based,
rather than the MitraClip robotic arm delivery system;
and new technologies that allow simpler, easier, and
more rapid percutaneous MV repair. Other catheter-
based technologies for treating MR are in develop-
ment. Indirect and direct percutaneous annuloplasty
approaches for MV repair have been done in humans
(60). Percutaneous approaches to MV replacement
have also been performed in animals and in human
cadavers (61,62). Improvements in procedural guid-
ance could shorten the procedure’s duration and
improve outcomes. Newer fusion imaging, combining
computed tomography and the widespread use of
3-dimensional echocardiography, might further en-
hance imaging and device delivery, and may poten-
tially shorten procedure time (63).
CONCLUSIONS
Percutaneous mitral valve repair therapy has emerged
as a novel therapy that may be safe and effective in
selected patients with MR. Although there is currently
insufﬁcient evidence to suggest that patients who
are suitable for surgery should be candidates for the
percutaneous therapy, recent data and results from
current registries suggest that percutaneous therapy
may be beneﬁcial in high-risk patient populations.
The percutaneous valve repair therapy system is
most appropriate for patients with primary MR who
are at high risk for surgery. Although nonrandomized
data suggest its efﬁcacy in patients with secondary/
functional MR, ongoing randomized clinical trials
are being conducted to conﬁrm the superiority of
the percutaneous approach to optimal medical
management.
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